| Literature DB >> 27105647 |
Xiao-Jun Lin1,2,3, Xiang-Ming Lao4,5,6, Ming Shi1,2,3, Sheng-Ping Li1,2,3.
Abstract
Unlike systemic chemotherapy for hematological malignancies with hepatitis B virus (HBV) infection, transarterial chemoembolization (TACE) for HBV-related hepatocellular carcinoma (HCC) has only recently been reported to cause HBV reactivation and subsequent hepatitis. Most patients with HBV-related HCC have an underlying disease with liver fibrosis or cirrhosis, and TACE may potentially induce HBV reactivation and liver decompensation. Currently, there are no clinical guidelines for managing TACE-caused HBV reactivation. In this review, we summarize the changes of HBV status and liver function after TACE and the effect of antiviral treatment before, during, or after TACE.Entities:
Keywords: Antiviral therapy; HBV reactivation; Hepatitis B virus; Hepatocellular carcinoma; Liver function; Nucleotide/nucleoside analogues; Transarterial chemoembolization
Mesh：
Substances：
Year: 2016 PMID： 27105647 DOI： 10.1007/s10620-016-4167-5
Source DB: PubMed Journal: Dig Dis Sci ISSN： 0163-2116 Impact factor: 3.199